Brind.

Hemostemix and Ocugen Receive Regulatory Approvals in The Bahamas

1 report, 1 independent Updated Oct 7
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Hemostemix Inc. received full approval from the National Longevity and Regenerative Therapy Board of The Bahamas for its commercial Phase 1 study of VesCellas. This treatment is being studied for angina, vascular dementia, and pain. Additionally, Ocugen, Inc. received provisional LARTA approval and priority designation for its investigational gene therapy OCU400, which targets retinitis pigmentosa.

From finanznachrichten.de

Why it matters

Some supportBrind's analysis of the reports

These approvals advance clinical programs within The Bahamas' growing longevity and regenerative-medicine sector. Hemostemix is also seeking price protection for a private placement to raise up to $1,000,000. Dr. Michael Darville, Minister of Health and Wellness, noted The Bahamas' reputation as a reputable location.

From finanznachrichten.de

Who's involved

  • The BahamasJurisdiction where the regulatory approvals for clinical trials were granted.
  • Michael DarvilleMinister of Health and Wellness who described The Bahamas as a reputable location.
  • HealthspanHealth mail-order supplier whose strategic expansion might be supported by the regulatory action.
  • BahamasCanadian singer-songwriter whose reputation might be boosted by the regulatory approval.
  • New ProvidenceDistrict-island of The Bahamas where improved reputation might attract localized investment.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped